Tyrosine kinase inhibitors as antiangiogenic drugs in multiple myeloma

Pharmaceuticals

Volumn 3, Issue 4, 2010, Pages 1225-1231

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Antiangiogenesis; Multiple myeloma; Tyrosine kinase inhibitors

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BORTEZOMIB; DASATINIB; GW 654652; IMATINIB; MELPHALAN; MIDOSTAURIN; PAZOPANIB; PREDNISONE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; SU 10991; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB;

BRAIN ISCHEMIA; CATALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVE SITE; HUMAN; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; REVIEW; THROMBOEMBOLISM;

EID: 77952177688     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3041225     Document Type: Review

References (30)

1. Imai, K.; Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6, 714-727.
2. Bergers, G.; Song, S.; Meyer-Morse, N.; Bergsland, E.; Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111, 1287-1295.
3. Inai, T.; Mancuso, M.; Hashizume, H.; Baffert, F.; Haskell, A.; Baluk, P.; Hu-Lowe, D.D.; Shalinsky, D.R.; Thurston, G.; Yancopoulos, G.D.; McDonald, D.M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 2004, 165, 35-52.
4. Kane, R.C.; Farrell, A.T.; Saber, H.; Tang, S.; Williams, G.; Jee, J.M.; Liang, C.; Booth, B.; Chidambaram, N.; Morse, D.; Sridhara, R.; Garvey, P.; Justice, R.; Pazdur, R. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 2006, 12, 7271-7278.
5. Cabebe, E.; Wakelee, H. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Drugs Today (Barc) 2006, 42, 387-398.
6. Morabito, A.; Piccirillo, M.C.; Falasconi, F.; De Feo, G.; Del Giudice, A.; Bryce, J.; Di Maio, M.; De Maio, E.; Normanno, N.; Perrone, F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009, 14, 378-390.
7. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S.D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, J.P.; Daly, T; Wiegand, S.J.; Yancopoulos, G.D.; Rudge, J.S. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 2002, 99, 11393-11398.
8. Vacca, A.; Ribatti, D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006, 20, 193-199.
9. Zhang, H.; Vakil, V.; Braunstein, M.; Smith, E.L.; Maroney, J.; Chen, L.; Dai, K.; Berenson, J.R.; Hussain, M.M.; Klueppelberg, U.; Norin, A.J.; Akman, H.O.; Ozçelik, T.; Batuman, O.A. Circulating endothelial progenitor cells in multiple myeloma: Implications and significance. Blood 2005, 105, 3286-3294.
10. Scavelli, C.; Nico, B.; Cirulli, T.; Ria, R.; Di Pietro, G.; Mangieri, D.; Bacigalupo, A.; Mangialardi, G.; Coluccia, A.M.; Caravita, T.; Molica, S.; Ribatti, D.; Dammacco, F.; Vacca, A. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 2008, 27, 663-674.
11. Nico, B.; Mangieri, D.; Crivellato, E.; Vacca, A.; Ribatti, D. Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev. 2008, 17, 19-22.
12. Ria, R.; Todoerti, K.; Berardi, S.; Coluccia, A.M.L.; De Luisi, A.; Mattioli, M.; Ronchetti, D.; Morabito, F.; Guarini, A.; Petrucci, M.T.; Dammacco, F.; Ribatti, D.; Neri, A.; Vacca, A. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin. Cancer Res. 2009, 15, 5369-5378.
13. Ribatti, D.; Nico, B.; Vacca, A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006, 25, 4257-4266.
14. Zhang, J.; Sattler, M.; Tonon, G.; Grabher, C.; Labadidi, S.; Zimmerhackl, A.; Raab, M.S.; Vallet, S.; Zhou, Y.; Cartron, M.A.; Hideshima, T.; Tai, Y.T.; Chauhan, D.; Andersin, K.C.; Podar, K. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1 alpha-dependent pathway in multiple myeloma. Cancer Res. 2009, 69, 5082-5090.
15. Lin, B.; Podar, K.; Gupta, D.; Tai, Y.T.; Li, S.; Weller, E.; Hideshima, T.; Lentzsch, S.; Davies, F.; Li, C.; Weisberg, E.; Schlossman, R.L.; Richardson, P.G.; Griffin, J.D.; Wood, J.; Munshi, N.C.; Anderson, K.C. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002, 62, 5019-5026.
16. Pandiella, A.; Carvajal-Vergara, X.; Tabera, S.; Mateo, G.; Gutierrez, N.; San Miguel, J.F. Imatinib mesylate (ST 1571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br. J. Haematol. 2003, 123, 858-868.
17. Dispenzieri, A.; Gertz, M.A.; Lacy, M.Q.; Gerey, S.M.; Griepp, P.R.; Rajkumar, S.V.; Kimlinger, T.; Lust, J.A.; Fonseca, R.; Allred, J.; Witzig, T.E. A phase II trial of imatinb in patients with refractory/relapsed myeloma. Leuk. Lymphoma 2006, 47, 39-42.
18. Zangari, M.; Anaissie, E.; Stopeck, A.; Morimoto, A.; Tan, N.; Lancet, J.; Cooper, M.; Hannah, A.; Garcia-Manero, G.; Faderl, S.; Kantarjian, H.; Cherrington, J.; Albitar, M.; Giles, F.J. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin. Cancer Res. 2004, 10, 88-95.
19. TM), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma. Invest. New Drugs 2006, 24, 529-535.
20. Podar, K.; Tonon, G.; Sattler, M.; Tai, Y.T.; Legouill, S.; Yasui, H.; Ishitsuka, K.; Kumar, S.; Kumar, R.; Pandite, L.N.; Hideshima, T.; Chauhan, D.; Anderson, K.C. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl. Acad. Sci. USA 2006, 103, 19478-19483.
21. Podar, K.; Catley, L.P.; Tai, Y.T., Shringarpure, R.; Carvalho, P.; Hayashi, T.; Burger, R.; Schlossman, R.L.; Richardson, P.G.; Pandite, L.N.; Kumar, R.; Hideshima, T.; Chauhan, D.; Anderson, K.C. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 2004, 103, 3474-3479.
22. Prince, H.M.; Hönemann, D.; Spencer, A.; Rizzieri, D.A.; Stadtmauer, E.A.; Roberts, A.W.; Bahlis, N.; Tricot, G.; Bell, B.; Demarini, D.J.; Benjamin, Suttle, A.; Baker, K.L.; Pandite, L.N. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood 2009, 113, 4819-4820.
23. Ramakrishnan, V.; Timm, M.; Haug, J.L.; Kimlinger, T.K.; Wellik, L.E.; Witzig, T.E.; Rajkumar, S.V.; Adjei, A.A.; Kumar, S. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010, 29, 1190-1202.
24. Coluccia, A.M.; Cirulli, T.; Neri, P.; Mangieri, D.; Colanardi, M.C.; Gnoni, A.; Di Renzo, N.; Dammacco, F.; Tassone, P.; Ribatti, D.; Gambacorti-Passerini, C.; Vacca, A. Validation of PDGFR beta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008, 112, 1346-1356.
25. Avet-Loiseau, H.; Li, J.Y.; Facon, T.; Brigaudeau, C.; Morineau, N.; Maloisel, F.; Rapp, M.J.; Talmant, P.; Trimoreau, F.; Jaccard, A.; Harousseau, J.L.; Bataille, R. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res. 1998, 58, 5640-5645.
26. Keats, J.J.; Reiman, T.; Maxwell, C.A.; Taylor, B.J.; Larratt, L.M.; Mant, M.J.; Belch, A.R.; Pilarski, L.M. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003, 101, 1520-1529.
27. Qing, J; Du, X.; Chen, Y.; Chan, P.; Li, H.; Wu, P.; Marsters, S.; Stawicki, S.; Tien, J.; Totpal, K.; Ross, S.; Stinson, S.; Dornan, D.; French, D.; Wang, Q.R.; Stephan, J.P.; Wu, Y.; Wiesmann, C.; Ashkenazi, A. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest 2009, 119, 1216-1229.
28. Grand, E.K.; Chase, A.J.; Heath, C.; Rahemtulla, A.; Cross, N.C. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 2004, 18, 962-966.
29. Paterson, J.L.; Li, Z.; Wen, X.Y.; Masih-Khan, E.; Chang, H.; Pollett, J.B.; Trudel, S.; Stewart, A.K. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br. J. Haematol. 2004, 124, 595-603.
30. Trudel, S.; Ely, S.; Farooqi, Y.; Affer, M.; Robbiani, D.F.; Chesi, M.; Bergsagel, P.L. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004, 103, 3521-3528.